Showing results (41-50 of 68) with videos related to
Sort By:
Pageof 7
The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Acta Haematologica|June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell MalignanciesLindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.The Lancet. Oncology|November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialCarsten U Niemann, Talha Munir, Carol Moreno, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW StudyTalha Munir, Carol Moreno, Carolyn Owen, et al.British Journal of Haematology|March 30, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximabDavid J Allsup, David A Cairns, E Faye Samy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.Blood|April 8, 2025
Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TNJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.Pageof 7